This article is more than 5 years old. Information may no longer be current.

Patrick T. Ellinor, MD, PhD, outlines results from a GRADE trial substudy

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

SAN FRANCISCO - In this video, Patrick T. Ellinor, MD, PhD, cardiac electrophysiologist at Massachusetts General Hospital Institute for Heart, Vascular and Stroke Care, and associate professor of medicine at Harvard Medical School, discusses a substudy analysis of the multicenter, prospective GRADE trial, presented at the Heart Rhythm Society Annual Scientific Sessions.

The trial assessed a cohort of approximately 1,500 patients with reduced ejection fraction who received an implantable ICD, and results indicated a significantly reduced the incidence of appropriate ICD shocks among patients using ACE inhibitors. Subanalyses indicated an increased benefit from ACE inhibitor use among patients with ischemic rather than nonischemic cardiomyopathy. Ellinor also noted that the addition of beta-blockers to ACE inhibitor use offered no additional protective effects.

He concluded that, while an ICD shock does not serve as a "surrogate" for sudden death, the results remain compelling and emphasize the need to continue to pursue ACE inhibitor use within this population.